Translumina Therapeutics
Translumina Therapeutics is an India-headquartered manufacturer of interventional cardiovascular medical devices, including drug-eluting stents, drug-eluting balloons, and coronary balloons. Operating three ISO 13485:2016 certified facilities in India, Germany, and the Netherlands, it serves hospitals and interventional cardiologists in 40+ countries as India's largest domestic coronary stent player.
- Company typePrivate
- Founded2010
- HeadquartersNew Delhi, India
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Translumina Therapeutics does
Translumina Therapeutics is a manufacturer of interventional cardiovascular medical devices, headquartered in New Delhi, India, and described as India's largest domestic player in the coronary stents market. Founded in 2010, the company produces a four-category product portfolio: drug-eluting stents (including a proprietary Polymer-Free DES positioned as a breakthrough in stent safety), the Protege drug-eluting balloon, coronary balloons, and vascular accessories. Manufacturing is conducted across three ISO 13485:2016 certified facilities in Dehradun (India), Hechingen (Germany), and Helmond (Netherlands), serving hospitals, cardiac centers, and interventional cardiologists in 40+ countries with a workforce of 600+ employees.
The company generates revenue through direct hardware sales of cardiovascular devices to healthcare providers via an enterprise field-sales model, with quote-based, negotiated procurement typical of the medical device category. Translumina supplements its direct sales with KOL-targeted medical education programs including the TransAcademy platform, Expert Sessions, and webinar series such as 'IVL Unplugged' (with Shockwave) and 'Crossing Conversations in CTOs.' The product ecosystem is extended through strategic partnerships with Shockwave (IVL), SIS Medical, ACIST (intravascular imaging), and Asahi Intecc (guidewires and catheters).
Translumina's recent corporate activity indicates an active globalization strategy: two European acquisitions were completed in June 2023 (Blue Medical Devices in the Netherlands and Lamed), the company established direct operations in the UAE in May 2024, and MedTech veteran Probir Das was appointed CEO in October 2024. The company remains privately held, with Everstone disclosed as a significant growth-equity investor from a 2019 funding round of approximately $69.9 million.
Translumina Therapeutics firmographics
Firmographics- Name
- Translumina Therapeutics
- Legal name
- Translumina
- Website
- https://translumina.in
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Translumina Therapeutics is an India-headquartered manufacturer of interventional cardiovascular medical devices, including drug-eluting stents, drug-eluting balloons, and coronary balloons. Operating three ISO 13485:2016 certified facilities in India, Germany, and the Netherlands, it serves hospitals and interventional cardiologists in 40+ countries as India's largest domestic coronary stent player.
- Ownership category
- akta.pro rank
Translumina Therapeutics industry classification
Industry- Product category
- Interventional Cardiovascular Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
- akta.pro primary industry
- Coronary Stents & Drug-Eluting Technologies (HLAHAFAA)
- akta.pro secondary industry
- Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy) (HLAHAFAE)
Keywords
Where Translumina Therapeutics is headquartered
LocationHeadquarters
- HQ city
- New Delhi
- HQ country
- India
- HQ region
- Asia
Offices3 records
Markets served
Translumina Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Cardiovascular Medical Devices Sales: Sale of interventional cardiovascular devices including drug-eluting stents, drug-eluting balloons, coronary balloons, and vascular accessories to healthcare providers globally.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Translumina Therapeutics product offering
Product offeringCore offering
Translumina Therapeutics designs, develops, and manufactures interventional cardiovascular medical devices, including drug-eluting stents (featuring proprietary polymer-free technology), drug-eluting balloons (Protege), coronary balloons, and vascular accessories. The company sells these products to hospitals, cardiac centers, and interventional cardiologists globally through direct enterprise sales channels.
Product overview
Translumina Therapeutics is a global leader in interventional cardiovascular devices offering a comprehensive portfolio of four core product categories: Drug Eluting Stents (including polymer-free technology), Drug Eluting Balloons (Protege), Coronary Balloons, and Vascular Accessories. The company operates manufacturing facilities in India, Germany, and the Netherlands, serving 40+ countries with ISO 13485:2016 certified quality standards.
Differentiator
Problem solved
Functional benefit
Brands
- TransAcademy: Educational/training platform for medical professionals
Products and services
- Drug Eluting Stents State-of-the-art drug-eluting stents for cardiovascular care, featuring polymer-free technology that redefines performance and improves stent safety, intended for hospitals and interventional cardiologists performing percutaneous coronary interventions.
- Drug Eluting Balloons (Protege) Cutting-edge drug-eluting balloons for vascular treatment, enabling localized drug delivery during percutaneous coronary interventions, targeted at interventional cardiology departments.
- Coronary Balloons Advanced coronary balloons for cardiovascular interventions, designed for optimal trackability and inflation performance during angioplasty procedures, used by interventional cardiologists.
- Vascular Accessories Precision vascular accessories supporting cardiovascular interventions, designed to achieve exceptional clinical outcomes in catheterization labs and interventional cardiology settings.
Companies that use Translumina Therapeutics
Customer profileSegments2 records
Ideal customer profiles2 records
Translumina Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Translumina Therapeutics partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and major.
- Blue Medical DevicescoreTranslumina acquired Blue Medical Devices, Netherlands in June 2023 to further strengthen its technology portfolio, expanding capabilities in the European market.
- LamedcoreTranslumina acquired Lamed to extend its European reach, expanding distribution and market presence in Europe.
- ShockwavemajorStrategic partnership for intravascular lithotripsy (IVL) technology and co-marketing initiatives including 'IVL Unplugged' webinar series.
- SIS MedicalmajorStrategic partnership for cardiovascular intervention technologies under the strategic partnerships section of the website.
- ACISTmajorStrategic partnership for intravascular imaging and diagnostic technologies in cardiovascular care.
- Asahi InteccmajorStrategic partnership for advanced guidewire and catheter technologies supporting complex cardiovascular interventions.
Scale indicators3 records
Recent moves7 records
Expansion highlights5 records
Translumina Therapeutics competitors and assessment
Company assessmentDirect peers
- Sahajanand Medical Technologies: Indian manufacturer of drug-eluting stents and cardiovascular devices, directly competing with Translumina in India's coronary stent market and several emerging markets. Closest head-to-head domestic competitor.
- Meril Life Sciences: Indian interventional cardiology device manufacturer producing DES (Meerabi), balloons, and structural heart products. Directly comparable in product portfolio, scale, and emerging-market GTM approach.
Broad incumbents
- Abbott: Global medtech leader with the Xience DES franchise — the gold-standard DES against which Translumina's polymer-free stent must compete. Dominant share in developed markets and clinical-evidence incumbent.
- Boston Scientific: Owner of the Synergy/Promus DES platform and other interventional cardiology franchises; sets competitive benchmarks in DES innovation, clinical evidence, and physician engagement globally.
- Medtronic: Major DES competitor with Resolute and Onyx platforms; large global interventional cardiology portfolio with deep KOL and clinical-trial infrastructure that Translumina must leverage or compete against.
Peers
Market position
Strengths4 records
Weaknesses3 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Translumina Therapeutics social profiles
Digital presenceTranslumina Therapeutics compliance and trust
Trust signalCompliance1 record
Translumina Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Translumina Therapeutics leadership team
Management profileNumber of profiles
Profiles5 records
Translumina Therapeutics subsidiaries and ownership
Company hierarchySubsidiaries2 records
Translumina Therapeutics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Translumina Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Translumina Therapeutics
What does Translumina Therapeutics do?
Translumina Therapeutics designs, develops, and manufactures interventional cardiovascular medical devices, including drug-eluting stents (featuring proprietary polymer-free technology), drug-eluting balloons (Protege), coronary balloons, and vascular accessories. The company sells these products to hospitals, cardiac centers, and interventional cardiologists globally through direct enterprise sales channels.
Is Translumina Therapeutics a public or private company?
Translumina Therapeutics is a private company. It is classified as private equity controlled and is currently operating.
When was Translumina Therapeutics founded?
Translumina Therapeutics was founded in 2010. It employs 251 to 500 people.
Where is Translumina Therapeutics based?
Translumina Therapeutics is headquartered in New Delhi, India, in the Asia region.
How does Translumina Therapeutics make money?
One revenue line is on record: cardiovascular Medical Devices Sales.
Who are Translumina Therapeutics's main competitors?
Direct peers on record are Sahajanand Medical Technologies and Meril Life Sciences. Broad incumbents are Abbott, Boston Scientific and Medtronic. Biotronik is listed as a peer.
Does Translumina Therapeutics have an API?
No public API is recorded for Translumina Therapeutics.
What industry is Translumina Therapeutics in?
Translumina Therapeutics's product category is Interventional Cardiovascular Devices. Its primary akta.pro industry code is HLAHAFAA, Coronary Stents & Drug-Eluting Technologies, with a secondary code of HLAHAFAE, Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy). Its NAICS code is 339112 and its SIC code is 3841.